RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
706. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey
PS y cols. Congestive heart failure in dialysis patients: prevalence,
incidence, prognosis and risk factors. Kidney Int 47:
884-890, 1995.
707. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy
RP y cols. Cardiovascular disease risk status in elderly persons
with renal insufficiency. Kidney Int 62: 997-1004,
2002
708. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine
concentration and risk of cardiovascular disease: a possible
marker for increased risk of stroke. Stroke 28: 557-563,
1997
709. Culleton BF, Hemmelgarn BR. Is chronic kidney disease a
cardiovascular disease risk factor? Semin Dialysis 16: 95-
100, 2003
710. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem
DN, Griffith JL y cols. Level of kidney function as a risk factor
for atherosclerotic cardiovascular disease in the community.
J Am Coll Cardiol 41: 47-55, 2003
711. O`Brien MM, Gonzales R, Shroyer AL, Grunwald GK, Daley
J, Henderson WG y cols. Modest serum creatinine elevation
affects adverse outcome after general surgery. Kidney Int 62:
585-592, 2002
712. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B,
Griffith JL, y cols. Chronic kidney disease as a risk factor for
cardiovascular disease and all cause mortality: a pooled
analysis of community based studies. J Am Soc Nephrol 15:
1307-1315, 2004.
713. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC
y cols. Prognostic significance of microalbuminuria in insulin
dependent diabetes mellitus : a twenty three year follow
up study. Kidney Int 41: 836-839, 1992
714. Stehouwer CD, Lambet J, Donker AJ, van Hinsbergh VW.
Endothelial dysfunction and pathogenesis of diabetic angiopathy.
Cardiovasc Res 34: 55-68, 1997
715. Festa A, D`Agostino R, Howard G, Mykkanen L, Tracy RP,
Haffner SM. Inflammation and microalbuminuria in non diabetic
and type 2 diabetic subjects: the insulin resistance
atherosclerosis study. Kidney Int 58: 1703-1710, 2000
716. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ,
Parving HH y cols. Increased urinary albumin excretion,
endothelial dysfunction, and chronic low grade inflammation
in type 2 diabetes: progressive, interrelated, and independently
associated with risk of death. Diabetes 51: 1157-
1165, 2002
717. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: From
physiology to therapy. J Mol Cell Cardiol 31: 61-74, 1999
718. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar
ME, y cols. Endothelin and cardiovascular remodelling in
end stage renal disease. Nephrol Dial Transplant 13: 375-
383,1998
719. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant
in uremia: oxidant stress as a unifying concept of cardiovascular
disease in uremia. Kidney Int 62: 1524-
1538,2002
720. Arici M, Walls J. End stage renal disease, atherosclerosis, and
cardiovascular mortality: Is C-reactive protein the missing
link? Kidney Int 2001; 59: 407-414
721. Massy Z, Nguyen-Khoa T. Oxidative stress and chronic renal
failure. Markers and management. J Nephrol 15: 336-341,
2002
722. Stenvinkel P. Interactions between inflammation, oxidative
stress, and endotelial dysfunction in end stage renal disease.
J Ren Ntr 13: 144-148, 2003
723. Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C,
Zoccali C. Oxidative stress in end stage renal: an emerging
threat to patient outcome. Nephrol Dial Transplant 18: 1272-
1280,2003
724. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Grego F,
Pauletto P y cols. New markers of accelerated atherosclerosis
in end stage renal disease. J Nephrol 16: 11-20,2003
725. Ruilope LM. Kidney Dysfunction: a sensitive predictor of
cardiovascular risk. Am J Kidney Dis. Am J Hypertens 14 (6
Pt 2): S213-S217, 2001
726. Levin A. Prevalence of cardiovascular damage in early renal
disease. Nephrol Dial Transplant 16 (suppl 2): 7-11, 2001
727. National Kidney Foundation K/DOQI clinical practice guidelines
on managing dyslipidemias in chronic kidney disease.
Am J Kidney Dis 41 (suppl 3): S1-S77,2003
728. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron
B, Larsson R y cols. Lipoprotein abnormalities are associated
with increased rate of progression of human chronic renal
insufficiency. Nephrol Dial Transplant 12: 1908-1915, 1997
729. Keane WF. The role of lipids in renal disease: Future challenges.
Kidney Int 57 (suppl 75): S27-S31, 2000
730. Kasiske BL. Hyperlipidemia in patients with chronic renal
disease. Am J Kidney Dis 32 (suppl 3): S142-S156, 1998
731. Warwick GL, Packard CJ. Lipoprotein metabolism in the
nephrotic syndrome. Nephrol Dial Transplant 8: 385-396,
1993
732. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ y cols.
Plasma lipids and risk of developing renal dysfunction: The
Atherosclerosis Risk in Communities Study. Kidney Int 58:
293-301,2000
733. López Revuelta K, Saracho R, García López F, Gentil MA,
Castro P, Castilla J y cols. Informe de diálisis y trasplante año
2001 de la Sociedad Española de Nefrología y Registros
Autonómicos. Nefrología 24: 21-33, 2004
734. National Kidney Foundation. K/DOQI clinical practice guidelines
for chronic kidney disease: evaluation, classification
and stratification. Am J Kidney Dis 39(2 suppl 1): S1-S266,
2002
735. Instituto Nacional de Estadística. Definiciones según la
causa de muerte 1999. Madrid. INE 2002
736. Sahadevan M, Kasiske B. Hyperlipidemia in kidney disease:
causes and consequences. Curr Opin Nephrol 11:323-329,
2002
737. Attman PO; Alaupovic P, Tavella M, Knight- Gibson C.
Abnormal lipid and apolipoprotein composition of major
lipoprotein density classes in patients with chronic renal failure.
Neprhol Dial Transplant 11: 63-69, 1996
738. Craig WY, Neveux LM, Palomaki GE, Cleveland MM,
Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart
disease : metaanalysis of prospective studies. Clin Chem 44:
2301-2306, 1998
739. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, y
cols. Lipoprotein(a) serum concentrations and apolipoprotein(a)
phenotypes in mild and moderate renal failure. J Am
Soc Nephrol 11: 105-115 , 2000
740. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI,
Hoff HF y cols. Lipoprotein(a) is an independent risk factor
209